Mogy Joel R Investment Counsel Inc. Increases Position in Eli Lilly and Company $LLY

Mogy Joel R Investment Counsel Inc. boosted its position in Eli Lilly and Company (NYSE:LLY) by 1.4% in the 2nd quarter, Holdings Channel reports. The fund owned 39,528 shares of the company’s stock after purchasing an additional 527 shares during the period. Eli Lilly and Company makes up about 1.8% of Mogy Joel R Investment Counsel Inc.’s investment portfolio, making the stock its 20th biggest position. Mogy Joel R Investment Counsel Inc.’s holdings in Eli Lilly and Company were worth $30,813,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Duquesne Family Office LLC grew its position in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after purchasing an additional 32,640 shares during the period. Corient IA LLC acquired a new stake in Eli Lilly and Company in the 1st quarter worth about $570,000. LS Investment Advisors LLC grew its holdings in Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP acquired a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $14,866,000. Finally, Prism Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter worth about $207,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $762.84 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $939.86. The company has a market capitalization of $722.00 billion, a price-to-earnings ratio of 49.86, a PEG ratio of 1.06 and a beta of 0.47. The business has a 50-day moving average of $739.17 and a 200-day moving average of $772.98.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were paid a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Guggenheim lowered their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Leerink Partnrs cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Berenberg Bank restated a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday. Morgan Stanley reiterated an “overweight” rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $939.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.